Abstract:
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.
Abstract:
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.
Abstract:
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.
Abstract:
The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit β-secretase.
Abstract:
The present invention relates to methods of modifying nematode behavior using certain isolated modulator compounds. Also disclosed are methods of promoting or inhibiting reproduction in a nematode population, methods of promoting or inhibiting nematode aggregation at a first location, and methods of treating or preventing parasite infection of a plant.
Abstract:
We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.
Abstract:
The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit β-secretase.
Abstract:
A composition comprising:(a) from 20 to 60 wt % of a saccharide component comprising from two to five sugar ring units having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to oxygen atoms on said sugar rings and at least three acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide; and(b) from 40 to 80 wt % of a non-saccharide component comprising a polyol unit not containing a sugar ring and having a hydroxyl functionality from two to five; said polyol unit having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to hydroxyl oxygen atoms of the polyol and at least two acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide;wherein total polymerized units of at least one alkylene oxide comprise from 20 to 80 wt % of said multi-functional additive.
Abstract:
Purified alkoxylated sucrose esters of the formula: wherein R is independently selected from: COR′; (CH2CH2O)xH; and (CH2CH2O)x COR′; wherein R′ is a fatty acid compound having from about 2 to about 28 carbon atoms; and wherein x is a number selected from about 1 to about 50; wherein at least one of the R groups is an ester group that is directly esterified to the sucrose backbone; and wherein the alkoxylated sucrose ester composition further comprises: less than 1% aldehydes; less than 1% ketones; less than 1% benzyl halide; less that 1% mono-benzyl ether; less than 1% acetals; and less than 1% ketals.
Abstract:
The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is a bond or an essentially pharmacologically inactive linking residue; the GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment of fibrinogen, comprising a carboxylate moiety and a basic moiety located within the residue at a distance of 10-20 Å from each other; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin label or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity.